BeOne Medicines AG is a fast-growing oncology company and a Wall Street favorite. Tevimbra, its PD-1 inhibitor, helped drive growth, with Q2 revenue rising 10.8% QoQ and 18.1% YoY to $228.5 million. BeOne's rich pipeline includes BGB-B2033, BG-C477, and BGB-58067, with clinical data scheduled for presentation at the 2026 ESMO Congress, taking place October 23-27.
Blackstone Strategic Credit 2027 Term Fund offers a floating-rate, high-yield portfolio with a current ~5% discount and ~8% yield. BGB's term structure is set for potential liquidation in under a year, creating a likely catalyst for discount narrowing via liquidation or a 100% NAV tender offer. Potential distribution increases may follow further Fed hikes, enhancing BGB's income appeal as well.
Blackstone Strategic Credit 2027 Term offers a widened discount exceeding 5.5%, now above our "Buy" threshold, prompting an upgrade. BGB's term structure and anticipated 2027 liquidation create a tactical opportunity, with a recent investment from a large institutional CEF investment group. The fund's floating-rate, senior secured loan portfolio provides diversification but carries leveraged below-investment-grade credit risk.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 780 | $8,830 | $8,466.9 | -$363.1 | -4.11% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 3.64M | $42.22M | $40.04M | -$2.17M | -5.15% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2,300 | $27,094 | $24,966.5 | -$2,127.5 | -7.85% |
| MB Mitchel Bialek Css LLC/IL | 72,187 | $839,844.38 | $788,282.04 | -$51,562.34 | -6.14% |
| MBV Matthew B. Vawter NATIONS FINANCIAL GROUP Inc., /IA/ /ADV | 11,686 | $126,368.27 | $127,611.12 | $1,242.85 | 0.98% |